AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Acquired IPR&D and Milestones Expense by Year
Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M)
AbbVie Acquired IPR&D and Milestones Expense: $602M in FY2025, down 38.3% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Earnings & Note 5.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 602 | -38.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 975 | +67.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 582 | +84.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 315 | +64.1% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 192 | -22.6% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 248 | -35.6% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 385 | -9.2% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 424 | +247.5% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 122 | -39.0% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 200 | +300.0% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 50 | – | Form 10-K (filed 2018-02-16) ↗ |
Breakdown
What makes up acquired IPR&D and Milestones Expense
Cite this data
StockData. (2026). AbbVie Acquired IPR&D and Milestones Expense ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/iprd-upfront-exp
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.